Pharmafile Logo
Pharmafocus logo
Advanced Search

Halaven

Showing 5 posts of 20 posts found.

Eisai launches cancer drug Halaven in UK

April 20, 2011
Sales and Marketing Eisai, Halaven, breast cancer

Eisai’s sea sponge derived breast cancer drug Halaven has been launched in the UK following approval from European regulators a …

News

Eisai marine sponge derived cancer drug approved in Europe

March 23, 2011
Sales and Marketing Cancer, Eisai, Halaven, Halichondria okadai, breast cancer, eribulin mesylate

Eisai’s injectible breast cancer drug Halaven has been approved by European regulators. The highly novel drug is made from a …

News

Eisai confirms 20% cut in US workforce

March 8, 2011
Manufacturing and Production, Research and Development, Sales and Marketing Aricept, Eisai, Halaven, US, donepezil, eribulin, pharma job cuts

Eisai’s planned job cuts will fall heaviest on its US operations, where 20% of the workforce will be let go …

News

Eisai prepares ground for Halaven’s European launch

March 7, 2011
Sales and Marketing Cancer, EMBRACE, Eisai, Halaven, advanced breast cancer, breast cancer, eribulin

Eisai has published further details of a phase III trial of its first-in-class chemotherapy drug Halaven ahead of its hoped-for …

News

FDA approves Eisai breast cancer drug Halaven

November 16, 2010
Sales and Marketing Cancer, Eisai, FDA, Halaven, Xeloda, breast cancer, eribulin mesylate, metastatic breast cancer

The FDA has approved Eisai’s advanced breast cancer drug Halaven for use in heavily pre-treated breast cancer patients. Halaven (eribulin …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026